Jiangsu Bioperfectus Technologies Co

Jiangsu Bioperfectus Technologies Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Jiangsu Bioperfectus Technologies Co (688399.SS) as of Nov 15, 2026 is 188.22. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 27.06 — a change of 595.59% (higher).

EV/OCF

188.22

YoY

595.59%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Jiangsu Bioperfectus Technologies Co is 2025 188.22 . EV/OCF (Enterprise Value to Operating Cash Flow) of Jiangsu Bioperfectus Technologies Co was 2024 27.06 . It decreases by 595.59% higher compared to the previous year.

The Jiangsu Bioperfectus Technologies Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
63.51 CNY
Jan 1, 2019
45.29 CNY
Jan 1, 2020
4.57 CNY
Jan 1, 2021
3.97 CNY
Jan 1, 2022
1.51 CNY
Jan 1, 2023
-29.73 CNY
Jan 1, 2024
27.06 CNY
Jan 1, 2025
188.22 CNY
The Jiangsu Bioperfectus Technologies Co EV/OCF history
YEAREV/OCFYoY
188.22+595.59%
27.06-191.02%
-29.73-2,074.18%
1.51-62.10%
3.97-13.03%
4.57-89.91%
45.29-28.69%
63.51-30.66%
91.58-64.19%
255.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jiangsu Bioperfectus Technologies Co Stock analysis

What does Jiangsu Bioperfectus Technologies Co do? Jiangsu Bioperfectus Technologies Co., Ltd. generates revenue through the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company's primary products include in vitro diagnostic reagents, supporting testing instruments, and in vitro testing services, which are utilized in infectious disease prevention and control, clinical testing, large-scale population screening, and prenatal and postnatal care management. Domestic and overseas markets represent the main sales channels for these products, with the firm targeting healthcare providers and laboratories that require diagnostic solutions for disease detection and patient care. The company's focus on in vitro diagnostic reagents and supporting instruments positions it within the healthcare sector, serving customers who need reliable testing tools for clinical and public health applications. By offering comprehensive diagnostic solutions, Jiangsu Bioperfectus addresses the needs of medical institutions and public health initiatives, particularly in areas such as infectious disease management and maternal care. The firm's product portfolio supports both routine clinical testing and specialized population screening programs. Jiangsu Bioperfectus Technologies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jiangsu Bioperfectus Technologies Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Jiangsu Bioperfectus Technologies Co is 188.22 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Jiangsu Bioperfectus Technologies Co changed from 27.06 to 188.22, representing a 595.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Jiangsu Bioperfectus Technologies Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Jiangsu Bioperfectus Technologies Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Jiangsu Bioperfectus Technologies Co

All Key Metrics — Jiangsu Bioperfectus Technologies Co